Ropes & Gray advised Takeda Pharmaceuticals on the deal. Takeda Pharmaceuticals announced it has entered into a collaboration and exclusive license agreement with Degron Therapeutics (“Degron”)...
You must be a Standard 1 Year member to access this content.
Baker McKenzie acted as legal counsel to Takeda. Takeda signed a worldwide license and collaboration agreement with Protagonist Therapeutics, Inc., for the development and commercialization of...
You must be a Standard 1 Year member to access this content.
Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...
You must be a Standard 1 Year member to access this content.
Morgan Lewis represented Takeda Pharmaceutical Company Limited in its transaction with clinical-stage rare disease therapeutics company Oak Hill Bio. Oak Hill Bio plans to advance a...
You must be a Standard 1 Year member to access this content.
Marval O’Farrell Mairal advised Takeda on the transaction Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has entered into an agreement to divest a selection of non-core products from the...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Takeda Pharmaceutical Company Limited in the deal. Takeda Pharmaceutical Company Limited announced an exclusive collaboration and license agreement with JCR Pharmaceuticals Co.,...
You must be a Standard 1 Year member to access this content.
Cleary Gottlieb Steen & Hamilton LLP represented Takeda Pharmaceutical Company Limited in the transaction. Takeda Pharmaceutical Company Limited, a global, research and development-driven biopharmaceutical company based...
You must be a Standard 1 Year member to access this content.
